Reverse Transcriptase Inhibitors
"Reverse Transcriptase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template.
| Descriptor ID |
D018894
|
| MeSH Number(s) |
D27.505.519.389.675.850 D27.505.954.122.388.077.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Reverse Transcriptase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Reverse Transcriptase Inhibitors".
This graph shows the total number of publications written about "Reverse Transcriptase Inhibitors" by people in this website by year, and whether "Reverse Transcriptase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2000 | 2 | 0 | 2 |
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 1 | 3 |
| 2007 | 3 | 1 | 4 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 2 | 0 | 2 |
| 2020 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Reverse Transcriptase Inhibitors" by people in Profiles.
-
Effect of HIV and antiretroviral therapy use on body weight changes in a cohort of U.S. veterans living with and without HIV. HIV Med. 2023 02; 24(2):180-190.
-
CYP2B6 516 G>T polymorphism and side effects of the central nervous system in HIV-positive individuals under Efavirenz treatment: Study of a sample from southern Brazil. An Acad Bras Cienc. 2017 May; 89(1 Suppl?0):497-504.
-
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis. 2014 Jul; 14(7):572-80.
-
Efficacy and safety of antiretrovirals in HIV-infected patients with cancer. Clin Microbiol Infect. 2014 Oct; 20(10):O672-9.
-
Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana. J Int Assoc Physicians AIDS Care (Chic). 2012 Jul-Aug; 11(4):260-8.
-
Transmitted HIV-1 drug resistance among young men of color who have sex with men: a multicenter cohort analysis. J Adolesc Health. 2011 Jan; 48(1):94-9.
-
Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells. Atherosclerosis. 2010 Jan; 208(1):104-11.
-
Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral therapy. Atherosclerosis. 2008 May; 198(1):192-7.
-
Treatment option for chronic hepatitis B. J Pak Med Assoc. 2001 Sep; 51(9):306-8.
-
A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS. 2000 Jul 28; 14(11):1591-600.